[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469262":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":45,"collaborators":47,"id":51,"slug":20,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tildrakizumab treatment","EXPERIMENTAL","Biological\u002Fvaccine: tildrakizumab",[13],"Drug: Tildrakizumab Prefilled Syringe",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Tildrakizumab Prefilled Syringe","IL-23 inhibitor",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Raymond Cho, MD, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","415-575-0524","rashes@ucsf.edu",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","San Francisco","California","94115","United States",{"type":38,"coordinates":39},"Point",[40,41],-122.41942,37.77493,{"lat":41,"lon":40},[44],{"name":23,"role":27,"phone":20,"phoneExt":20,"email":20},{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[48],{"name":49,"class":50},"Sun Pharmaceutical Industries Limited","INDUSTRY","100469262",false,"NCT05390515","Psoriatic Immune Response to Tildrakizumab","Inclusion Criteria:\n\n* 18 years of age or older\n* Patients with moderate-severe psoriasis or \\> 5% body surface area affected.\n\nExclusion Criteria:\n\n* taking systemic immunosuppressives in the last 4 weeks\n* pregnancy\n* severe immunodeficiency (either from genetic or infectious causes).\n* tuberculosis or other active serious infection\n* active systemic malignancy.\n* breast-feeding\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.","ALL","18 Years","75 Years",{"count":60,"type":61},10,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.",[67],"Psoriasis Vulgaris","2026-06-01",{"date":70,"type":71},"2026-06-04","ACTUAL",{"date":73,"type":71},"2022-09-01",{"date":75,"type":61},"2028-09-01",{"name":5,"class":6},1]